Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1799-1805

  Suzuki Jr , Emilio Rintaro ^a   Franklin, Luciana Meirelles ^a   Basilio Da Silva, Luciano José ^b   Figueiredo, Carlos R L ^a   Netto, Joao Agostini ^c   Batista, Wagner Duarte ^c  

^a Glaucoma Service of Santa Casa of Belo Horizonte   (Brazil)

^b Alcon Research Ltd   (Brazil)

^c Department of Ophthalmology of Santa Casa of Belo Horizonte ^*  (Brazil)

Author keywords

Dorzolamide; Glaucoma; Intraocular pressure; Timolol; Travoprost

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; TRAVOPROST;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; HYPEREMIA; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PARALLEL DESIGN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TASTE; TASTE DISORDER; TREATMENT DURATION;

CLOPROSTENOL; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; SINGLE-BLIND METHOD; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 33749025296     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X121020     Document Type: Article

References (23)

1. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005;22:1-21
2. Aref AA, Schmitt BP. Open-angle glaucoma: tips for earlier detection and treatment selection. J Fam Pract 2005;54:117-25
3. Francis BA, Du LT, Berke S, et al. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol - a randomized controlled trial and a replacement study. J Clin Pharm Ther 2004;29:375-80
4. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol 2004;15:119-26
5. Kirwan JF, Nightingale JA, Bunce C, et al. Beta-blockers for glaucoma and excess risk of airways obstruction: population based cohort study. Br Med J 2002;325:1396-7
6. Sugrue MF, Mallorga P, Schwam H, et al. A comparison of L-671, 152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animal. Curr Eye Res 1990;9:607-15
7. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1 year study comparing dorzolamide (Trusopt), timolol, and betaxolol [International Dorzolamide Study Group]. Arch Ophthalmol 1995;113:1009-16
8. Travatan [package insert]. Fort Worth, TX: Alcon Laboratories, Inc. 2004
9. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001;17:421-32
10. 4 prostanoid receptor. Br J Pharmacol 2000;130:1919-26
11. 3H]9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol 1999;51:685-948
12. Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414-22
13. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
14. Normas de pesquisa envolvendo seres humanos. Resolução N° 196/96 do Conselho Nacional de Saúde. An Bras Dermatol 1997;72(Suppl 1):30-40
15. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary-open angle glaucoma. Arch Ophthalmol 2002;120:701-13
16. Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia 2005;49: 39-45
17. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
18. Susanna Jr R, Sheu WP; Latin American Glaucoma Society. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America. Clin Ther 2004;26:755-68
19. Honrubia FM, Larsson LI, Spiegel D, et al. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 2002;80:635-41
20. Fechtner RD, McCarroll KA, Lines CR, et al. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 2005;21: 242-9
21. AGIS group. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration [The AGIS Investigators]. Am J Ophthalmol 2000;130:429-40
22. Chen PP, Park RJ. Visual field progression in patients with initially unilateral visual field loss from chronic open-angle glaucoma. Ophthalmology 2000;107:1688-92
23. DuBiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004;26:84-91